28.06.2014 Views

Autologous Bone Marrow Transplantation - Blog Science Connections

Autologous Bone Marrow Transplantation - Blog Science Connections

Autologous Bone Marrow Transplantation - Blog Science Connections

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Mafosfamide Purging in Leukemia 83<br />

Determination of the Optimal Mafosfamide Dose<br />

Because of the inability, at least with routine laboratory techniques, to<br />

evaluate the risk of injuring pluripotent stem cells when destroying all CFCI-GM,<br />

we defined the optimal mafosfamide dose for in vitro treatment of the whole BM<br />

as the dose that spares 5% of residual CFCI-GM. As shown in Figure 1, the LD 9 5<br />

definition zone for most patients spreads over 14-30 jug/2 x 10 7<br />

buffy coat<br />

cells. In our experience, this allowed an accurate and reliable determination of<br />

the appropriate dose on a PIT. In a series of 32 marrow-cleansing procedures<br />

(for 24 patients in the clinical trial and 8 additional ones), residual CFCI-GM were<br />

evaluated after incubation of the whole BM with the predetermined dose, and<br />

the results were compared with those given by the PIT. In 25 cases, in which all<br />

the technical parameters were adequate, the actual CFCI-GM recovery measured<br />

after treatment of collected marrow was correlated with the expected recovery<br />

predicted by the PIT curve (r = .473, P < .03), and accuracy of the recovery was ±<br />

4%. In the other seven cases, discrepancies were observed that could be<br />

retrospectively attributed either to an excessive hematocrit at time of bone<br />

marrow incubation, an inappropriately low temperature of the incubator, or the<br />

presence of cell aggregates. Figure 1 shows that if we decided to incubate all<br />

marrows with a standard dose of mafosfamide, rather than adapt the dose to<br />

each patient, the best choice of dose would be 70 ug/2 * 10 7<br />

cells, which would<br />

fit our objective of leaving 5% residual CFCI-GM in 35% of the patients. With this<br />

> » I I » ' * « * * ' • • • • «' — >STA 2 TitT ug/ 1 W calls<br />

D W 20 30 40 SO »0 '0 M> «O 100 HO 120 130 MO »50<br />

, 9 , MKiSD lufl/I 10%»«») o! tKli indiotdual P*ti««l |n=3H -J overall m«an t SO<br />

Figure 1. Individual susceptibility of granulocyte-macrophage colony-forming units to<br />

mafosfamide (Asta Z 7557). (Reproduced from Blood, vol. 67, 1986, with permission of<br />

Grune & Stratton.)

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!